Martín-Suárez A, Falcao A C, Outeda M, Hernández F J, González M C, Quero M, Arranz I, Lanao J M
Department of Pharmacy and Pharmaceutical Technology, University of Salamanca, Spain.
Ther Drug Monit. 2002 Dec;24(6):742-5. doi: 10.1097/00007691-200212000-00010.
Digoxin pharmacokinetics were studied in a pediatric population with an age range of 6 days to 1 year using the population pharmacokinetic approach. Digoxin data were analyzed by mixed-effects modeling according to a one-compartment steady-state pharmacokinetic model using NONMEM software. The final model selected for the population prediction of digoxin clearance in pediatric patients was as follows: [equation: see text] Individual empirical Bayesian estimates were generated on the basis of the population estimates and were used to correlate the optimum dose of digoxin and patient age according to the following equation: [equation: see text] This equation and its derived nomogram may be used for the initial dosing of digoxin in children aged between 0 and 1 year. The use of this nomogram in routine monitoring requires further pharmacokinetic and clinical validation.
采用群体药代动力学方法，在年龄范围为6天至1岁的儿科人群中研究了地高辛的药代动力学。使用NONMEM软件，根据一室稳态药代动力学模型，通过混合效应模型分析地高辛数据。为儿科患者群体预测地高辛清除率而选择的最终模型如下：[公式：见原文] 根据群体估计值生成个体经验贝叶斯估计值，并根据以下公式将其用于关联地高辛的最佳剂量与患者年龄：[公式：见原文] 该公式及其导出的列线图可用于0至1岁儿童地高辛的初始给药。在常规监测中使用此列线图需要进一步的药代动力学和临床验证。
